FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005752252> ?p ?o ?g. }

• W2005752252 abstract "Hepatitis A (infectious hepatitis) is a common epidemic disease. Immunoglobulins for passive immunisation are used as prevention.To assess the beneficial and harmful effects of the pre- and post-exposure prophylaxis with immunoglobulins for preventing hepatitis A.We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, The Chinese Biomedical Database, and Science Citation Index Expanded for trials until October 2008. In addition, we read through reference lists of the identified publications and handsearched three journals.Randomised clinical trials on immunoglobulin prophylaxis for preventing hepatitis A, irrespective of blinding, publication status, or language.Data were extracted by two authors and verified by a third author. Results were presented as relative risks (RR) with 95% confidence intervals (CI). The primary outcome was occurrence of hepatitis A (infectious hepatitis).We included 13 trials with 567,476 participants randomised to pre- or post-exposure prophylaxis. The trials had high risk of bias. The trials were heterogeneous in terms of study setting, participants, interventions, and outcome measures. Our meta-analysis with six randomised trials showed that immunoglobulins, when used for pre-exposure prophylaxis, significantly reduced the number of adult patients with hepatitis A at 6 to 12 months (1020/286503 versus 761/134529; RR 0.53; 95% CI 0.40 to 0.70; random-effects model) in comparison with no intervention or inactive control. Four trials showed a similar effect in children aged 3 to 17 at 6 to 12 months follow-up (917/210822 versus 677/78960; RR 0.45; 95% CI 0.34 to 0.59). Comparing different doses of immunoglobulins, higher dosage was generally more effective than lower dosage (1.5 ml better than 0.75 ml and 0.75 ml better than 0.1 ml) in preventing hepatitis A. No significant systemic adverse events were reported. One trial showed that immunoglobulin was more effective than placebo for post-exposure prophylaxis. It appeared that there was no significant difference between immunoglobulins and inactivated hepatitis A vaccine in seroconversion to hepatitis A vaccine antibodies at four weeks (RR 1.16; 95% CI 0.98 to 1.38), but immunoglobulins were significantly less effective than vaccine regarding antibody levels at 8, 12, or 24 weeks.Immunoglobulins seem to be effective for pre-exposure and post-exposure prophylaxis of hepatitis A. However, caution is warranted for the positive findings due to the limited number of trials, year of conductance, and risk of bias. Conductance of rigorous trials will be justifiable." @default.
• W2005752252 created "2016-06-24" @default.
• W2005752252 creator A5000238995 @default.
• W2005752252 creator A5015509624 @default.
• W2005752252 creator A5048910824 @default.
• W2005752252 date "2009-04-15" @default.
• W2005752252 modified "2023-10-12" @default.
• W2005752252 title "Immunoglobulins for preventing hepatitis A" @default.
• W2005752252 cites W151140654 @default.
• W2005752252 cites W1598602811 @default.
• W2005752252 cites W1964489041 @default.
• W2005752252 cites W1969470808 @default.
• W2005752252 cites W1970230664 @default.
• W2005752252 cites W1981342069 @default.
• W2005752252 cites W1984129081 @default.
• W2005752252 cites W2026539130 @default.
• W2005752252 cites W2036960093 @default.
• W2005752252 cites W2045259190 @default.
• W2005752252 cites W2048731767 @default.
• W2005752252 cites W2049563665 @default.
• W2005752252 cites W2072221058 @default.
• W2005752252 cites W2074795000 @default.
• W2005752252 cites W2075446267 @default.
• W2005752252 cites W2082930860 @default.
• W2005752252 cites W2083158405 @default.
• W2005752252 cites W2092116089 @default.
• W2005752252 cites W2093541354 @default.
• W2005752252 cites W2099525015 @default.
• W2005752252 cites W2117294447 @default.
• W2005752252 cites W2120299481 @default.
• W2005752252 cites W2122784612 @default.
• W2005752252 cites W2134338262 @default.
• W2005752252 cites W2135029321 @default.
• W2005752252 cites W2143842982 @default.
• W2005752252 cites W2145460315 @default.
• W2005752252 cites W2151846067 @default.
• W2005752252 cites W2157823046 @default.
• W2005752252 cites W2160795579 @default.
• W2005752252 cites W2177262332 @default.
• W2005752252 cites W2295878350 @default.
• W2005752252 cites W2313132104 @default.
• W2005752252 cites W2337114621 @default.
• W2005752252 cites W3024424248 @default.
• W2005752252 cites W337492223 @default.
• W2005752252 cites W4214559180 @default.
• W2005752252 cites W4238011299 @default.
• W2005752252 cites W4238504479 @default.
• W2005752252 cites W4239602713 @default.
• W2005752252 cites W4248985911 @default.
• W2005752252 cites W2165456085 @default.
• W2005752252 doi "https://doi.org/10.1002/14651858.cd004181.pub2" @default.
• W2005752252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19370595" @default.
• W2005752252 hasPublicationYear "2009" @default.
• W2005752252 type Work @default.
• W2005752252 sameAs 2005752252 @default.
• W2005752252 citedByCount "17" @default.
• W2005752252 countsByYear W20057522522012 @default.
• W2005752252 countsByYear W20057522522013 @default.
• W2005752252 countsByYear W20057522522014 @default.
• W2005752252 countsByYear W20057522522015 @default.
• W2005752252 countsByYear W20057522522019 @default.
• W2005752252 countsByYear W20057522522020 @default.
• W2005752252 countsByYear W20057522522023 @default.
• W2005752252 crossrefType "journal-article" @default.
• W2005752252 hasAuthorship W2005752252A5000238995 @default.
• W2005752252 hasAuthorship W2005752252A5015509624 @default.
• W2005752252 hasAuthorship W2005752252A5048910824 @default.
• W2005752252 hasConcept C126322002 @default.
• W2005752252 hasConcept C168563851 @default.
• W2005752252 hasConcept C187212893 @default.
• W2005752252 hasConcept C2771230 @default.
• W2005752252 hasConcept C2775876817 @default.
• W2005752252 hasConcept C2776029263 @default.
• W2005752252 hasConcept C2776478404 @default.
• W2005752252 hasConcept C2777382497 @default.
• W2005752252 hasConcept C2780799908 @default.
• W2005752252 hasConcept C44249647 @default.
• W2005752252 hasConcept C535046627 @default.
• W2005752252 hasConcept C71924100 @default.
• W2005752252 hasConcept C82789193 @default.
• W2005752252 hasConcept C95190672 @default.
• W2005752252 hasConceptScore W2005752252C126322002 @default.
• W2005752252 hasConceptScore W2005752252C168563851 @default.
• W2005752252 hasConceptScore W2005752252C187212893 @default.
• W2005752252 hasConceptScore W2005752252C2771230 @default.
• W2005752252 hasConceptScore W2005752252C2775876817 @default.
• W2005752252 hasConceptScore W2005752252C2776029263 @default.
• W2005752252 hasConceptScore W2005752252C2776478404 @default.
• W2005752252 hasConceptScore W2005752252C2777382497 @default.
• W2005752252 hasConceptScore W2005752252C2780799908 @default.
• W2005752252 hasConceptScore W2005752252C44249647 @default.
• W2005752252 hasConceptScore W2005752252C535046627 @default.
• W2005752252 hasConceptScore W2005752252C71924100 @default.
• W2005752252 hasConceptScore W2005752252C82789193 @default.
• W2005752252 hasConceptScore W2005752252C95190672 @default.
• W2005752252 hasLocation W20057522521 @default.
• W2005752252 hasLocation W20057522522 @default.
• W2005752252 hasOpenAccess W2005752252 @default.
• W2005752252 hasPrimaryLocation W20057522521 @default.
• W2005752252 hasRelatedWork W1885119863 @default.

• next